SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Pseudo Biologist who wrote (1200)8/11/1997 1:50:00 AM
From: scaram(o)uche   of 1762
 
Ah, come on Max, it was a figure of speech. Top ten didn't sound good enough. ;-)

OK...... angiogenesis, Alzheimer's, antivirals including vaccines, and antibiotics and potentiators. Now everyone will see that there is no cardiovascular and laugh me out of SI.

Jeff Ledbetter carried costimulatory molecules on his shoulders at Bristol-Myers Squibb and was later joined by Peter Linsley, King of CTLA-4/CD28. This effort was at the Research Institute in Seattle, derivative from Oncogen, derivative from Genetic Systems (the very first Blech company) and all derivative from the foresight of Bob Nowinski (sort of). You can read about the origins in "Gene Dreams" by Robert Teitelman.

Ed Clark (mentioned in my previous message, the individual who produced the first anti-B7) was one of the GS founders. He and I were grad students together in the same lab at UCLA. After postdocs, he went to GS and I went to Cutter (part of Bayer). Cutter had a partnership with GS for human anti-pseudomonas monoclonals, and I coordinated stuff from the Bayer/Cutter side. I therefore spent a lot of time walking around the facilities in Seattle. Jeff Ledbetter came later, but I had enough contact to know that he was brilliant and extremely hard working. In fact, the entire crew in Seattle was hard working. I'm not surprised that it evolved into such a strong program.

In any event, Bristol-Myers Squibb is a good place to look for control of CTLA-4/CD28.

Cheers! Rick
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News